New Compounds Hybrids 1H-1,2,3-Triazole-Quinoline Against Plasmodium falciparum

Malaria is one of the most prevalent parasitic diseases in the world. The global importance of this disease, current vector control limitations, and the absence of an effective vaccine make the use of therapeutic antimalarial drugs the main strategy to control malaria. Chloroquine is a cost‐effectiv...

Full description

Saved in:
Bibliographic Details
Published inChemical biology & drug design Vol. 84; no. 3; pp. 325 - 332
Main Authors Boechat, Núbia, Ferreira, Maria de Lourdes G., Pinheiro, Luiz C. S., Jesus, Antônio M. L., Leite, Milene M. M., Júnior, Carlos C. S., Aguiar, Anna C. C., de Andrade, Isabel M., Krettli, Antoniana U.
Format Journal Article
LanguageEnglish
Published HOBOKEN Blackwell Publishing Ltd 01.09.2014
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Malaria is one of the most prevalent parasitic diseases in the world. The global importance of this disease, current vector control limitations, and the absence of an effective vaccine make the use of therapeutic antimalarial drugs the main strategy to control malaria. Chloroquine is a cost‐effective antimalarial drug with a relatively robust safety profile, or therapeutic index. However, chloroquine is no longer used alone to treat patients with Plasmodium falciparum due to the emergence and spread of chloroquine‐resistant strains, which have also been reported for Plasmodium vivax. However, the activity of 1,2,3‐triazole derivatives against chloroquine‐sensitive and chloroquine‐resistant strains of P. falciparum has been reported in the literature. To enhance the anti‐P. falciparum activity of quinoline derivatives, we synthesized 11 new quinoline‐1H‐1,2,3‐triazole hybrids with different substituents in the 4‐positions of the 1H‐1,2,3‐triazole ring, which were assayed against the W2‐chloroquine‐resistant P. falciparum clone. Six compounds exhibited activity against the P. falciparum W2 clone, chloroquine‐resistant, with IC50 values ranging from 1.4 to 46 μm. None of these compounds was toxic to a normal monkey kidney cell line, thus exhibiting good selectivity indexes, as high 351 for one compound (11). Chloroquine (CQ) is no longer used alone to treat patients with Plasmodium falciparum due to the emergence and spread of CQ‐resistant strains. To enhance the anti‐P. falciparum activity of quinoline derivatives, we synthesized 11 new quinoline‐1H‐1,2,3‐triazole hybrids with different substituents in the 4‐positions of the 1H‐1,2,3‐triazole ring, which were assayed against the W2‐chloroquine‐resistant P. falciparum clone. Six compounds exhibited activity against the P. falciparum W2 clone with IC50 values ranging from 1.4 to 46 µm.
Bibliography:State of Minas Gerais (FAPEMIG)
Technological Development Program on Products for Health of Fiocruz (PDTIS)
ark:/67375/WNG-WW2MBKW3-B
istex:EFD25E64D39E4EC5B7BC3567E839AD2827DA7DC3
Foundations for Research of the State of Rio de Janeiro (FAPERJ)
ArticleID:CBDD12321
CNPq-MCT/MS (PRONEX Rede Malaria)
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1747-0277
1747-0285
DOI:10.1111/cbdd.12321